NCT00474955View on ClinicalTrials.gov

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Hepatitis C, Chronic
Interventions
DRUG

peginterferon alfa-2a [Pegasys]

180 micrograms or 135 micrograms sc weekly for 48 weeks

Trial Locations (5)

460040

Orenburg

664047

Irkutsk

672090

Chita

680009

Khabarovsk

680022

Khabarovsk

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00474955 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure. | Biotech Hunter | Biotech Hunter